FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308306703> ?p ?o ?g. }

• W4308306703 endingPage "7351" @default.
• W4308306703 startingPage "7343" @default.
• W4308306703 abstract "The World Health Organization (WHO) recommended ‘pre-vaccination screening’ as its preferred implementation strategy when using the licensed dengue vaccine (CYD-TDV; Dengvaxia, Sanofi), so that only individuals with previous dengue infection are vaccinated. The US Centers for Disease Control and Prevention (CDC) recommended use of CYD-TDV to prevent dengue in children with previous laboratory-confirmed dengue infection in regions where dengue is endemic. Here, we evaluate the public health impact and cost-effectiveness of a ‘pre-vaccination screening’ strategy in Puerto Rico. The current analysis builds upon a previously published transmission model used to assess the benefits/risks associated with dengue vaccination. For ‘pre-vaccination screening’, three alternative testing methods were assessed: one using an immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) dengue serotest, another with dengue serotesting using a rapid diagnostic test (RDT), and one using both sequentially (as recommended in Puerto Rico). The time horizon considered was 10 years. In Puerto Rico, the disability-adjusted life years (DALYs) averted for ‘pre-vaccination screening’ with an ELISA-based program, RDT-based program, and both sequentially would be a median 1,192 (95% CI: 716–2,232), 2,812 (95% CI: 1,579–5,019), and 1,017 (95% CI: 561–1,738), respectively. These benefits would arise from the reduction in cases: median 24,961 (95% CI: 17,480–36,782), 58,273 (95% CI: 40,729–84,796), 20,775 (95% CI: 14,637–30,374) fewer cases, respectively. The cost per DALY averted from a payer perspective would be US$12,518 (95 %CI: US$4,749–26,922), US$10,047 (95% CI: US$3,350–23,852), and US$12,334 (95% CI: US$4,965–26,444), respectively. All three strategies would be cost saving from a societal perspective. Our study supports the WHO and CDC ‘pre-vaccination screening’ guidance for CYD-TDV implementation. In Puerto Rico, regardless of the testing strategy and even with a relatively low rate of testing, it would be cost-effective from a payer perspective and cost saving from a societal perspective." @default.
• W4308306703 created "2022-11-10" @default.
• W4308306703 creator A5001059480 @default.
• W4308306703 creator A5013688853 @default.
• W4308306703 creator A5027897513 @default.
• W4308306703 creator A5050548152 @default.
• W4308306703 creator A5075324282 @default.
• W4308306703 creator A5086033366 @default.
• W4308306703 date "2022-11-01" @default.
• W4308306703 modified "2023-09-28" @default.
• W4308306703 title "Public health impact and cost-effectiveness of implementing a ‘pre-vaccination screening' strategy with the dengue vaccine in Puerto Rico" @default.
• W4308306703 cites W1977473516 @default.
• W4308306703 cites W2020497948 @default.
• W4308306703 cites W2041439128 @default.
• W4308306703 cites W2053490656 @default.
• W4308306703 cites W2073245703 @default.
• W4308306703 cites W2106069784 @default.
• W4308306703 cites W2109111344 @default.
• W4308306703 cites W2123858885 @default.
• W4308306703 cites W2131222241 @default.
• W4308306703 cites W2161119181 @default.
• W4308306703 cites W2175735255 @default.
• W4308306703 cites W2287808237 @default.
• W4308306703 cites W2333788799 @default.
• W4308306703 cites W2468062764 @default.
• W4308306703 cites W2469018819 @default.
• W4308306703 cites W2508682720 @default.
• W4308306703 cites W2519603001 @default.
• W4308306703 cites W2529957341 @default.
• W4308306703 cites W2568134545 @default.
• W4308306703 cites W2598019380 @default.
• W4308306703 cites W2607456321 @default.
• W4308306703 cites W2774571722 @default.
• W4308306703 cites W2807989886 @default.
• W4308306703 cites W2885921047 @default.
• W4308306703 cites W2887984741 @default.
• W4308306703 cites W2888876305 @default.
• W4308306703 cites W2894843815 @default.
• W4308306703 cites W2916890405 @default.
• W4308306703 cites W2952094509 @default.
• W4308306703 cites W2972646493 @default.
• W4308306703 cites W2980375583 @default.
• W4308306703 cites W2981034519 @default.
• W4308306703 cites W2981538215 @default.
• W4308306703 cites W2996240102 @default.
• W4308306703 cites W3018845879 @default.
• W4308306703 cites W3036476797 @default.
• W4308306703 cites W3142712071 @default.
• W4308306703 cites W3186214996 @default.
• W4308306703 cites W4200261130 @default.
• W4308306703 cites W4239159649 @default.
• W4308306703 doi "https://doi.org/10.1016/j.vaccine.2022.10.071" @default.
• W4308306703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36347720" @default.
• W4308306703 hasPublicationYear "2022" @default.
• W4308306703 type Work @default.
• W4308306703 citedByCount "2" @default.
• W4308306703 countsByYear W43083067032023 @default.
• W4308306703 crossrefType "journal-article" @default.
• W4308306703 hasAuthorship W4308306703A5001059480 @default.
• W4308306703 hasAuthorship W4308306703A5013688853 @default.
• W4308306703 hasAuthorship W4308306703A5027897513 @default.
• W4308306703 hasAuthorship W4308306703A5050548152 @default.
• W4308306703 hasAuthorship W4308306703A5075324282 @default.
• W4308306703 hasAuthorship W4308306703A5086033366 @default.
• W4308306703 hasBestOaLocation W43083067031 @default.
• W4308306703 hasConcept C112930515 @default.
• W4308306703 hasConcept C138816342 @default.
• W4308306703 hasConcept C159110408 @default.
• W4308306703 hasConcept C203014093 @default.
• W4308306703 hasConcept C22070199 @default.
• W4308306703 hasConcept C2779308166 @default.
• W4308306703 hasConcept C2779635636 @default.
• W4308306703 hasConcept C3019080777 @default.
• W4308306703 hasConcept C533803919 @default.
• W4308306703 hasConcept C71924100 @default.
• W4308306703 hasConcept C99454951 @default.
• W4308306703 hasConceptScore W4308306703C112930515 @default.
• W4308306703 hasConceptScore W4308306703C138816342 @default.
• W4308306703 hasConceptScore W4308306703C159110408 @default.
• W4308306703 hasConceptScore W4308306703C203014093 @default.
• W4308306703 hasConceptScore W4308306703C22070199 @default.
• W4308306703 hasConceptScore W4308306703C2779308166 @default.
• W4308306703 hasConceptScore W4308306703C2779635636 @default.
• W4308306703 hasConceptScore W4308306703C3019080777 @default.
• W4308306703 hasConceptScore W4308306703C533803919 @default.
• W4308306703 hasConceptScore W4308306703C71924100 @default.
• W4308306703 hasConceptScore W4308306703C99454951 @default.
• W4308306703 hasFunder F4320307781 @default.
• W4308306703 hasIssue "50" @default.
• W4308306703 hasLocation W43083067031 @default.
• W4308306703 hasLocation W43083067032 @default.
• W4308306703 hasOpenAccess W4308306703 @default.
• W4308306703 hasPrimaryLocation W43083067031 @default.
• W4308306703 hasRelatedWork W2179712232 @default.
• W4308306703 hasRelatedWork W2202324402 @default.
• W4308306703 hasRelatedWork W2508682720 @default.
• W4308306703 hasRelatedWork W2510055542 @default.
• W4308306703 hasRelatedWork W2756226472 @default.

• next